Claritev (NYSE:CTEV) EVP Michael Kim Buys 9,600 Shares

Claritev (NYSE:CTEV) EVP Michael Kim purchased 9,600 shares of the stock in a transaction on Monday, November 17th. The stock was acquired at an average cost of $38.25 per share, for a total transaction of $367,200.00. Following the acquisition, the executive vice president owned 105,529 shares in the company, valued at approximately $4,036,484.25. This represents a 10.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Claritev Stock Up 10.3%

Shares of NYSE CTEV opened at $42.05 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 310.26. The business has a 50-day moving average of $57.41 and a 200-day moving average of $49.25. The firm has a market capitalization of $695.09 million, a price-to-earnings ratio of -2.01 and a beta of 0.42. Claritev has a 12 month low of $4.80 and a 12 month high of $74.07.

Institutional Investors Weigh In On Claritev

A number of institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. bought a new position in shares of Claritev during the 3rd quarter valued at $42,000. Legal & General Group Plc purchased a new stake in Claritev during the third quarter valued at about $45,000. BNP Paribas Financial Markets bought a new position in shares of Claritev during the third quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Claritev during the third quarter valued at about $187,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Claritev in the third quarter worth about $322,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CTEV shares. Citigroup raised their price objective on shares of Claritev from $74.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Claritev presently has a consensus rating of “Hold” and an average price target of $80.00.

Claritev Company Profile

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services.